INVA Innoviva, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Innoviva, Inc. (INVA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on February 25, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Innoviva, Inc. (INVA) (SEC CIK 1080014), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: diversified biopharmaceutical company with royalties portfolio plus critical care and infectious disease operating platform (Innoviva Specialty Therapeutics)
- • New products launched: XACDURO® (2023), ZEVTERA® (Q3 2025), and FDA approval of NUZOLVENCE® (Dec 2025) for infectious diseases
Risk Factors
- • FDA approval of NUZOLVENCE® in Dec 2025, with commercialization planned in H2 2026, regulatory risk around market launch and adoption timing
- • Pricing pressures in U.S. caused 2% decline in royalty revenue to $236.5M in 2025, signaling macroeconomic risk on revenue from GSK royalty portfolio
Management Discussion & Analysis
- • Revenue details and YoY change not disclosed in provided MD&A excerpt
- • Profitability or margin data not included in provided text
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New operational risk: FDA Priority Review of zoliflodacin with PDUFA date Dec 15, 2025, no advisory committee meeting planned (triggered by NDA acceptance in June 2025)
- • Most materially updated financial risk: Convertible noteholders converted $192.5M principal to 11.1M shares in Aug 2025, reducing debt and interest expense
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q results press release attached as Exhibit 99.1 — refer to exhibit for all financial figures and key metrics
- • Filing furnished (not filed) under SEC rules — limits legal liability, standard practice for earnings releases
Annual Reports Archive10-K
AI-powered analysis of Innoviva, Inc. (INVA) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Innoviva, Inc. (INVA) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Innoviva, Inc. (INVA) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $331.3M | $310.5M | $358.7M | $411.3M |
| Gross Profit | — | $246.0M | $296.2M | $307.7M |
| Operating Income | — | $113.9M | $166.9M | $163.7M |
| Net Income | — | $179.7M | $23.4M | $271.2M |
| Gross Margin | — | 79.2% | 82.6% | 74.8% |
| Op. Margin | — | 36.7% | 46.5% | 39.8% |
| Net Margin | — | 57.9% | 6.5% | 65.9% |
| Balance Sheet | ||||
| Total Assets | — | $1.2B | $1.3B | $1.6B |
| Equity | $565.8M | $675.0M | $691.2M | $1.2B |
| ROE | — | 26.6% | 3.4% | 23.1% |
Source: XBRL financial data from Innoviva, Inc. (INVA) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Feb 25, 2026 | — | Analysis | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 7, 2025 | Mar 31, 2025 | — | |
10-K | Feb 26, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Jul 31, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 1, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Jul 27, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 27, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 29, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 28, 2021 | Mar 31, 2021 | — | |
10-K | Feb 25, 2021 | Dec 31, 2020 | — | |
10-Q | Oct 28, 2020 | Sep 30, 2020 | — | |
10-Q | Jul 29, 2020 | Jun 30, 2020 | — | |
10-Q | Apr 29, 2020 | Mar 31, 2020 | — |
Frequently Asked Questions
What are the latest INVA SEC filings in 2026?
Innoviva, Inc. (INVA) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on February 25, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did INVA file its most recent 10-K annual report?
Innoviva, Inc. (INVA) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view INVA 10-Q quarterly reports?
Innoviva, Inc. (INVA)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every INVA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has INVA filed recently?
Innoviva, Inc. (INVA)'s most recent 8-K was filed on February 25, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find INVA insider trading activity (Form 4)?
SignalX aggregates every INVA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does INVA file with the SEC?
Innoviva, Inc. (INVA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new INVA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Innoviva, Inc. (INVA).
What is INVA's SEC CIK number?
Innoviva, Inc. (INVA)'s SEC CIK (Central Index Key) number is 1080014. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1080014 to look up all INVA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find INVA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Innoviva, Inc. (INVA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Innoviva, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 55+ filings.